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Abstract
Background: Aneuploidy, centrosome abnormalities and gene amplification are hallmarks of chromosome
instability (CIN) in cancer. Yet there are no studies of the in vivo behavior of these phenomena within the same
bladder tumor.
Methods: Twenty-one paraffin-embedded bladder tumors were analyzed by conventional comparative genome
hybridization and fluorescence in situ hybridization (FISH) with a cyclin D1 gene (CCND1)/centromere 11 dual-color
probe. Immunofluorescent staining of a, b and g tubulin was also performed.
Results: Based on the CIN index, defined as the percentage of cells not displaying the modal number for
chromosome 11, tumors were classified as CIN-negative and CIN-positive. Fourteen out of 21 tumors were
considered CIN-positive. All T1G3 tumors were included in the CIN-positive group whereas the majority of Ta
samples were classified as CIN-negative tumors. Centrosome clustering was observed in six out of 12 CIN-positive
tumors analyzed. CCND1 amplification in homogeneously staining regions was present in six out of 14 CIN-positive
tumors; three of them also showed amplification of this gene in double minutes.
Conclusions: Complex in vivo behavior of CCND1 amplicon in bladder tumor cells has been demonstrated by
accurate FISH analysis on paraffin-embedded tumors. Positive correlation between high heterogeneity, centrosome
abnormalities and CCND1 amplification was found in T1G3 bladder carcinomas. This is the first study to provide
insights into the coexistence of CCND1 amplification in homogeneously staining regions and double minutes in
primary bladder tumors. It is noteworthy that those patients whose tumors showed double minutes had a
significantly shorter overall survival rate (p < 0.001).
Background
Malignant tumors typically arise from multiple events
within the developing cancer cells. Genetic damage is a
hallmark of malignant cells and plays a key role in both
the initiation and the progression of tumorigenesis [1].
Bladder cancer, along with most solid tumors, is char-
acterized by multiple numerical and structural chromo-
some aberrations which in general associate with
progression [2,3]. Amplification of 11q13 involving
cyclin D1 gene (CCND1) is among the most common
sites of gene amplification in T1-T2 high grade tumors
[4-6]. Cyclin D1 plays an important role in cell cycle,
binds to cyclin dependent kinases (CDK4/6), and pro-
motes phosphorylation of RB1, orchestrating progression
through the G1 restriction point.
Gene amplification involving oncogenes, a common
mechanism to overexpress cancer-related genes, might
be present in cancer cells as double-minute chromo-
somes (DMs) or homogeneously staining regions
(HSRs). DMs are circular extrachromosomal autono-
mously-replicating DNA fragments lacking a centro-
mere. HSRs are amplified intrachromosomal sequences
that may be located in the same region of the amplified
gene or in another chromosomal region [7]. The 11q13
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amplicon is generally located at the same chromosome
region of the single-copy genes involved (CCND1, etc.)
[8]; other amplifications, such as those involving MYCN
in neuroblastomas, are inserted in several places in the
genome other than chromosome 2, where MYCN gene
is mapped [9,10].
Numerical chromosome instability (CIN), which
occurs very frequently in cancer cells [11], contributes
to aneuploidy and plays a critical role in tumorigenesis
as a key element of genomic instability [11,12]. Chromo-
some missegregation resulting from the deregulation of
the spindle checkpoint is thought to be a potential
cause of CIN. However, the molecular basis of this cau-
sative relation remains largely unknown [13]. The cen-
trosome, a major microtubule-organizing center in
animal cells, plays a vital role during mitosis as a spindle
pole, and is crucial for accurate chromosome segrega-
tion to daughter cells [14]. In previous studies, centro-
some amplification, defined as an increase in the
centrosome number, has been identified in many differ-
ent tumors, including bladder cancer [15,16]. In addi-
tion, centrosome amplification has been recently shown
to initiate tumorigenesis in flies [17]. Several studies
have demonstrated that centrosomal abnormalities and
chromosome copy-number heterogeneity frequently co-
exist in bladder tumor cells [18-20]. More recently, Jin
et al. [21] found that multipolar mitosis and anaphase
bridges are common, often concurrent, mitotic abnorm-
alities in urothelial carcinomas, both in vivo and
in vitro. The same authors identified several types of
chromosome segregation abnormalities, including telo-
mere dysfunction, sister-chromatid non-disjunction, and
supernumerary centrosomes in urothelial cancer cell
lines. These studies strongly support the hypothesis that
CIN is present in bladder carcinomas.
The aim of this study was to describe how CCND1
amplicons and chromosome 11 copy number heteroge-
neity represent in vivo features of chromosomal instabil-
ity in superficial bladder carcinomas. To that end, 21
paraffin-embedded cancer tissue samples were analyzed
using comparative genomic hybridization (CGH) and
fluorescence in situ hybridization (FISH). In seeking a
basis for the chromosomal heterogeneity, we investi-
gated centrosome and mitotic spindle integrity by
immunofluorescent staining. Our results demonstrate,
for the first time, that CCND1 amplification in DM and
HSR could co-exist in the same bladder tumor. A corre-
lation between HSR fragmentation and the appearance
of DMs, which were subsequently eliminated by micro-
nuclei extrusion, was also observed. Interestingly, we
found that those patients whose tumors showed CCND1
amplification in DMs had a significantly shorter overall
survival rate. Finally, the correlation between chromo-
some instability and centrosome abnormalities showed
that the coalescence of centrosomes into two functional
spindle poles was common in unstable bladder tumors.
Methods
Samples
Twenty-one formalin-fixed and paraffin embedded blad-
der-tumor samples were obtained from the Fundació
Puigvert and Hospital del Mar of Barcelona. Tumor
stage and grade were defined according to WHO criteria
[22]. All tumors were superficial or minimally invasive
(nine pTa, 12 pT1). Of 21 cases, six were grade 1, eight
were grade 2 and seven were grade 3. Clinical and histo-
pathological data are indicated in table 1. In one patient
(case U-443), the first recurrence of the tumor and the
penile and inguinal lymph node metastases were also
studied.
Conventional comparative genomic hybridization
For each tumor sample, DNA was extracted from four
to five 10 μm paraffin sections using a Qiagen Kit:
QIAamp® DNA Mini Kit. Before extraction, evaluation
by the pathologist determined that the proportion of
tumor cells was higher than 80%. The first and the last
sections were stained with hematoxylin/eosin to ensure
the presence of tumor in the sections series. Compara-
tive genomic hybridization analysis was performed
according to the method described by Prat et al.[3].
CCND1 amplification and CIN analysis
CIN generates intercellular numerical variation for the
same chromosome within a given tumor. Fluorescence
in situ hybridization analysis can be considered as a
practical method to detect CIN in surgical specimens
[23]. In this study, CEP 11 was used as the copy-number
reference of chromosome 11. FISH was carried out
using Spectrum Orange-labeled CCND1 and Spectrum
Green-labeled CEP 11 (Vysis Inc., Downers Grove, IL).
Five μm sections from representative tissue blocks were
used in this study. Briefly, slides were placed in the oven
for 30 min at 65°C and paraffin was dissolved in Xylene.
Slides were boiled in EDTA 1 mM, followed by a pepsin
treatment. Post-fixation was performed in 1% formalde-
hyde. Co-denaturation of the slide material and the
probes was carried out according to the manufacturer’s
instructions using a Hybrite (Vysis Inc.). Hybridization
took place overnight at 37°C in a moist chamber. Nuclei
were counterstained with 4’,6-Diamidino-2-Phenylindole
(DAPI, Sigma) diluted on Vectashield antifade solution
at a final concentration of 125 ng/μl. Analysis was done
under a fluorescence microscope (Olympus BX-50). A
minimum of 280 cells were scored in each case.
CIN index was defined as the percentage of cells not dis-
playing the modal copy number for the studied chromo-
some [16,23], in this case chromosome 11. The samples
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were graded according to their CIN index, as negative CIN
(<30% of the cells with non-modal signal number), moder-
ate (>30% <60% of the cells) and high CIN (> 60% of the
cells). FISH was also applied in order to analyze the ampli-
fication of CCND1 gene. Amplification was only consid-
ered when it appeared in HSR or DM forms.
Immunofluorescent analysis of centrosome and mitotic
spindle
Briefly, 5 μm sections from representative tissue blocks
were de-paraffinized in xylene, and then rehydrated in
ddH2O through graded alcohols. Slides were boiled in
1 mM EDTA buffer (pH.8) and then were incubated
overnight at 4°C in PBTG solution (PBS, 0.2% BSA,
0.2% gelatin, and 0.05% Tween 20) with primary rabbit-
polyclonal g-tubulin (T3559, Sigma-Aldrich, 1:100) and
mouse-monoclonal a-tubulin (T5168, Sigma-Aldrich,
1:200) and b-tubulin (T4026, Sigma-Aldrich, 1:200). Sig-
nal detection was performed applying fluorochrome-
conjugated secondary antibodies (all from Jackson
ImmunoResearch Laboratories): goat anti-rabbit Cy3
(diluted 1:1,000 in PBTG) and goat anti-mouse Cy5
antibody (diluted 1:1,000 in PBTG). Secondary anti-
bodies were incubated for 1 h at 37°C. Four PBTG
washes were carried out. Fixation was performed in 1%
formaldehyde. Tissue sections were counterstained with
DAPI and then examined under a fluorescence micro-
scope (Olympus BX-50).
Measurements of centrosome lengths were made
using the MicroMeasure v3.3 software http://www.
Table 1 Patient characteristics and study results
Case Age/
Sex
Stage/
Grade
S/
M
CIS Modal
number
Chr 11
CIN
index
CGH
11q13
FISH
CCND1
Subpop SC
(%)
C
size
(μm)
AC MS
(%)
Recurrence
(months)
Survival CRD
CIN
negative
U-400 45/♂ TaG1 S - 2 17.64 normal normal No 0 0.8 - 0 0 >6 years No
U-114 63/♀ TaG1 S - 2 20 normal normal No 3.8 1.10 - 0 1;(19) >6 years No
U-408 66/♂ TaG2 S + 2 20.18 normal normal No 0 0.98 - 0 3;(4),(60),(8) >6 years No
U-814 68/♂ T1G2 M - 2 23.97 gain gain No 1 0.63 - 0 5;(8),(15),(34),
(43),(3)
>5 years No
U-373 52/♀ TaG2 M - 2 25.9 normal normal No 0 0.9 - 0 1;(37) >6 years No
U-906 58/♂ TaG1 S - 2 25.41 normal normal No 1 0.81 - 0 1;(67) >5 years No
U-433 68/♂ TaG1 S + 2 28.75 normal normal No ? ? ? ? 1;(28) >6 years No
Moderate
CIN
U-611 54/♂ T1G3 S + 2 33.7 normal normal No 0 2.04 + 0 0 >42
months
No
U-443 62/♂ T1G3 S - 2 34.16 amp HSR Yes (3) 0 0.98 - 0 3;(17),(13)*,(34)
*
67
months
Yes
U-955 48/♂ TaG1 S - 2 37.91 normal normal No 0 0.8 - 0 0 >6 years No
U-089 45/♂ TaG2 S - 2 43.33 normal normal No 5 1.21 + 0 2;(8),(13) >5 years No
U-150 60/♂ T1G2 S - 2 43.51 amp HSR,
DM
Yes (2) 21 4.88 + 0 5;(10),(17),(9),
(6),(7)
54
months
Yes
U-617 67/♂ TaG1 S - 2 47.5 normal normal No ? ? ? ? 2;(9),(11) >6 years No
U-013 73/♂ T1G2 S + 2 54.83 normal normal No 4 1.06 - 0 0 >41
months
No
U-532 51/♂ T1G3 M + 2 57.14 normal gain No 38 0.68 + 7 0 >6 years No
High CIN U-076 67/♂ T1G3 M + 2 60.41 amp HSR,
DM
Yes (2) 20 2.22 + 17 3;(9),(4),(10) 31
months
Yes
U-866 40/♂ T1G3 M + 3 65.68 normal gain,
HSR,
DM
Yes (3) 0 5.69 + 0 - 36
months
Yes
U-364 73/♂ T1G3 S - 2 67.61 normal gain,
HSR1,
HSR2
Yes (3) 27 2.06 + 17 0 >3
months
No
U-183 62/♂ T1G3 M + 3 70 normal HSR No 5 1.18 + 0 0 >6 years No
U-466 71/♂ T1G2 S - 4 70.66 gain gain No ? ? ? ? 1;(14) >6 years No
U-564 55/♂ T1G2 S - 2 70.68 loss gain No 0 2.01 + 0 2;(10),(3) >6 years No
S: single, M: multiple, CIS: carcinoma in situ, CIN index: percentage of cells not displaying the modal copy number for chromosome 11, subpop: presence and
number of intratumor subpopulations, defining subpopulation as a group of cells with a distinctive chromosomal alteration (numerical or structural) at a specific
area on the tumor, amp: amplification, HSR: homogeneously staining region, HSR1,2: different types of homogeneously staining region, DM: double minute, SC:
percentage of cells displaying supernumerary centrosomes (>2 centrosomes), C size: average size of centrosome, AC: presence of abnormal centrosomes (size >2
μm or number >2 in at least 5% of cells), MS: percentage of cells displaying multipolar spindle, *: metastasis, CRD: cancer related death, ?: data not available
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biology.colostate.edu/micromeasure. The presence of
supernumerary centrosomes was considered whenever
the centrosome number was ≥3 in at least 5% of the
cells. Abnormally large centrosomes (diameter ≥2 μm)
were indicative of centrosome clustering.
Statistical analysis
The statistical analysis of the data was carried out by
using the SPSS software package (SPSS Inc; Chicago, IL,
USA; Version 15.0). Overall survival was estimated with
the Kaplan-Meier method. The survival curves were sta-
tistically compared by a log-rang test. Fisher’s exact test
was used to find associations. p < 0.05 was considered
statistically significant.
Results
Classification of tumors according to the CIN index
Depending on the percentage of cells with a number of
chromosome 11 different from the modal number,
tumors were classified into three groups: high, moderate
and negative CIN (Table 1). Samples showing an inter-
cellular variation in the number of centromeric signals
for chromosome 11 greater than 30% were deemed to
have chromosomal instability. Fourteen out of 21 sam-
ples (66%) were classified into the CIN-positive group.
CIN-negative tumors showed a modal number of 2
using a centromere-specific FISH probe for chromo-
some 11. Only a small fraction of the tumor cells
showed monosomy, while trisomy was even less fre-
quent (Figure 1A). Within the CIN-positive group,
tumors with moderate CIN levels had a modal number
of 2. CIN-moderate samples showed a greater chromo-
some 11 copy number range than CIN-negative group,
with trisomy the most frequently observed (Figure 1B).
The high CIN tumors had wide-ranging chromosome
11 copy numbers (Figure 1C). Monosomy was rare; the
modal number was disomic in three samples, trisomic
in two samples, and tetrasomic in only one sample.
There was a positive correlation between the CIN
index and the tumor grade (Figure 1D). Moreover, the
majority of Ta G1/G2 tumors (6/9) were included in the
CIN-negative group whereas T1G3 tumors were exclu-
sively found in high CIN (4/7) or moderate CIN (3/7)
groups (Table 1).
Centrosome defects and multipolar mitoses
In seeking a basis for the observed chromosomal hetero-
geneity, we investigated centrosome and spindle integ-
rity using immunofluorescent staining. Results were
obtained for 18 of the 21 samples. In general, there was
a positive correlation between the CIN index and cen-
trosome abnormalities (p < 0.005). We have used the
terms supernumerary centrosomes and centrosome clus-
tering to describe the abnormalities of the centrosomes
observed in our study. Despite the fact that both terms
imply the presence of extra centrosomes, we considered
centrosome clustering when centrosomes could be
microscopically observed as abnormally-shaped or large
centrosomes and supernumerary centrosomes when
they were observed individually.
Spindle errors were not present in samples with nor-
mal centrosome numbers (Figure 2A-B). In our study,
supernumerary centrosomes were the most frequent
aberration identified. The presence of enlarged centro-
somes or shape aberrations such as string-like centro-
somes (Figure 2C-E), which are indicative of centrosome
clustering, was also frequently observed (Table 1). All
the high CIN samples (n = 5) showed abnormal centro-
somes. Overall, supernumerary centrosomes and centro-
some clustering were found in 60% and 80% of the
tumors, respectively (Figure 2F-J). In two samples (U-
076 and U-364), both centrosome alterations were con-
comitant. In the moderate CIN group, four out of the
seven samples (57%) showed abnormal centrosomes.
Supernumerary centrosomes were found in three sam-
ples, while centrosome clustering was present in two. In
one of them (U-150), both alterations were found simul-
taneously (Table 1). Centrosome abnormalities were
absent in normal tissue adjacent to the tumor cells
(Figure 2E). String-like centrosomes were found in three
samples (U-150, U-866 and U-564) (Figure 2C-E). The
longest centrosome was found in sample U-150 (7.33
μm). These extraordinarily long centrosomes were
involved in the formation of bipolar spindles (Figure
2C-D, Table 1).
Multipolar and/or pseudo-bipolar mitoses were
observed in three out of six samples (50%) with super-
numerary centrosomes (Figure 2F-I). Coalescence of
supernumerary centrosomes into two functional spindle
poles was observed in all samples with enlarged
centrosomes.
CCND1 gene amplification: FISH vs. CGH
The copy number status of CCND1 was analyzed using
FISH and conventional CGH (Table 1). CCND1 amplifi-
cation was identified by FISH in most of the high-CIN
samples (four out of six), in 25% of the moderate-CIN
samples (two out of eight) and in none of the CIN nega-
tive samples. Concordance between FISH and CGH
results was observed in 16 out of 21 cases (76%); all
samples with disagreement between FISH and CGH
results were CIN-positive. Sample U-532 showed no
11q13 gain using CGH; however, 42% of cells within
this sample showed five or more copies of CCND1
using FISH, even though the modal number was 2. The
most divergent results were found in high-CIN tumors.
Three samples (U-866, U-364 and U-183) showed
CCND1 amplification using FISH, although it was not
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detected using CGH. Sample U-564 showed a whole
chromosome 11 loss by CGH, however more than five
copies in 23% of the cells were detected using FISH. In
summary, amplification of the CCND1 in DMs and/or
HSRs was detected using FISH in six cases; amplifi-
cation was detected using CGH only in three cases
(U-443, U-150 and U-076).
Intratumor cell sub-populations and CCND1 amplification
behavior
By accurately analyzing the samples showing CCND1
amplification, various cell sub-populations were detected
within the tumors. A cell sub-population is defined as a
group of cells with a distinctive chromosomal alteration
(numerical or structural) at a specific area of the tumor.
Analysis of these sub-populations provided insights into
the in vivo behavior of CCND1 amplification.
Discrete cell sub-populations were found in three
samples (U-076, U-866 and U-364) with a high CIN
index and in two (U-443, U-150) with a moderate CIN
index (Table 1). Sample U-076 had two sub-populations:
one showed CCND1 amplification in HSRs, while the
other showed amplification in DMs, probably due to
excision from HSRs. There were also intermediate con-
formations, as shown in Figure 3A-H. DMs and HSRs
are readily identifiable at the metaphase stage, but can
also be distinguished in interphase nuclei. While HSRs
are seen as a compact and distinct signal, DMs showed
a diffuse signal. The co-existence of DMs and HSRs was
also detected in two other samples (U-150 and U-866).
Sample U-364 showed a complex pattern of CCND1
amplification. Three sub-populations were detected in
this sample, including one with whole chromosome
gain up to nine copies (Figure 3I); two sub-populations
showed CCND1 amplification as two HSRs, both of
which varied significantly in terms of structure and
size. One sub-population generated an amplicon with a
high CCND1 copy number, which was viewed during
the metaphase stage as a long CCND1-positive HSR
(Figure 3J). The other sub-population showed a differ-
ent amplification pattern, with fewer CCND1 copies,
each of which was surrounded by some undetermined
genomic material, as seen during the metaphase stage
(Figure 3K).
In patient U-443, it was possible to analyze the beha-
vior of the amplicon over a period of time. CCND1
amplification as a compact HSR was detected in the pri-
mary tumor, its recurrence and penile metastasis (after
17 and 30 months, respectively). However, diffuse HSR
amplification and a small fraction of cells with DMs
were observed in an inguinal lymph node metastasis
detected 34 months after the penile metastasis. These
results suggest that HSRs could remain stable during
long periods before giving rise to DMs during a late-
metastasis. (The patient died three months following the
metastasis).
Figure 1 Chromosome 11 copy number variability. (A) Negative-CIN tumors. (B) Moderate-CIN tumors. (C) High-CIN tumors. (D) CIN index vs.
tumour grade correlation.
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It is noteworthy that those patients, whose primary
tumors showed DMs had cancer-related deaths. The
Kaplan-Meier analysis showed that these patients (U-
150, U-76 and U-866) had a significantly shorter overall
survival rate than patients without DMs in their primary
tumors (including U-443) (p < 0.001). Therefore we
concluded that high heterogeneity samples showed dif-
ferent populations with amplification of CCND1 and it
correlates with clinical features.
DMs distribution on the metaphase plate, micronuclei,
internuclear bridges and nuclear blebs
This analysis was carried out on samples showing
CCND1 gene amplification in DMs (samples U-150, U-
076 and U-866) (Table 2). DMs containing CCND1
were predominantly located in the peripheral region of
the metaphase plate (Figure 3L-O) (Table 2). Meta-
phases were analyzed in paraffin-embedded tissue sec-
tions, allowing the identification of DMs containing
CCND1 non-randomly located at the periphery during
metaphase in bladder primary tumors.
All samples with DMs showed nuclear blebs and
micronuclei, whereas the samples without DMs did not.
The size of the micronuclei varied from 5-30% of
nuclear volume. The number of micronuclei per 100
cells varied from 10-13 (Table 2). In samples U-150 and
U-076, a significant percentage of micronuclei were
CCND1-positive (45% and 40% respectively) (Figure 3P-
Q). Approximately 2% of the micronuclei in these sam-
ples were positive for chromosome 11 centromere. In
sample U-866, there were 10 micronuclei per 100 cells,
being 24% of them CCND1-positive. This tumor had a
higher proportion of micronuclei positive for centro-
mere 11 (24%), indicating a very high level of aneu-
ploidy, compared with the previous two samples (U-076
and U-150). The complete removal of DMs by micronu-
cleus extrusion, giving rise to cells with two or three
CCND1 gene copies, was also observed in a small
Figure 2 Centrosome abnormalities. Immunolabeling was performed for g-tubulin (red) and a and b-tubulin (green). DNA staining was
performed with DAPI (blue). Black and white images correspond to DAPI reverse staining. (A-B) Normal/bipolar spindle. (C-D) Bipolar metaphase
with string-like centrosome. (E) Tumour cells with abnormally long centrosomes, close to the adjacent normal urothelium. (F-G) Multipolar
spindle. (H-I) Pseudo-bipolar metaphase. (J) Tumour cells with supernumerary centrosomes. Scale bar, 3 μm.
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Figure 3 CCND1 amplification behaviour in bladder tumors. FISH identification of chromosome 11 centromere (green) and CCND1 gene
(red) in paraffin-embedded tumors. DNA staining was performed with DAPI (blue). Black and white images correspond to DAPI reverse staining.
(A-H) Metaphasic cells showing the proposed sequence of 11q13 amplicon fragmentation from HSRs to DMs. (I-K) Sample U-364 showed a
complex pattern of CCND1 amplification. Three sub-populations were detected in this sample. (I) Sub-population with gain of whole
chromosome 11. (J) Sub-population containing HSR with high-level amplification of CCND1 (K) Sub-population containing amplification of CCND1
and undetermined flanking material in HSR. (L-O) Peripheral location of DMs in metaphasic cells. (P-Q) CCND1-positive micronuclei, see arrows. In
Q, note the elimination in the micronucleus of whole CCND1 copies, except those attached to the centromere. (R) Metaphasic cells containing a
dicentric chromosome with two centromeric signals of chromosome 11 and CCND1 amplification, see asterisks. (S and T) CCND1 with HSRs
appears to be forming internuclear bridges, see arrows. (U and V) Nuclear blebs as nuclear protrusions with high CCND1 signal.
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number of cells (Figure 3P-Q). The presence of meta-
phase dicentric chromosomes, internuclear bridges, and
nuclear blebs positive for the CCND1 amplification
demonstrated the ongoing chromosomal instability
observed in high CIN bladder primary tumors (Figure
3R-V).
Discussion
In the present study, the gene copy number variation
analysis of CCND1 in formalin fixed paraffin embedded
tissue sections revealed a complex and unprecedented
pattern of cellular behavior in non-muscle invasive blad-
der tumors. Our results suggested that copy number
changes of CCND1 could be used as a biomarker to
detect chromosome instability in bladder cancer. Blad-
der tumors were classified according to the CIN index,
and we have shown a positive correlation between high
heterogeneity, centrosome abnormalities and CCND1
gene amplification.
A positive correlation between the level of chromoso-
mal instability and the tumor grade was identified; this
phenomenon was previously described in bladder cancer
[16]. Focusing exclusively on chromosome 11, the pre-
sent study classifies the majority of Ta tumors as stable
(CIN-negative group). These results are in agreement
with the 2004 WHO classification that distinguishes two
different entities in non-muscle invasive bladder tumors:
one (Ta low-grade G1/G2) genetically stable in which
gene amplifications are rare, and the other (T1 high-
grade) with a high degree of genetic instability including
high level amplifications [24]. Despite the low number
of samples analyzed, it is remarkable that our classifica-
tion of tumors according to their CIN index included all
T1G3 samples in the CIN-positive group. CIN-negative
group was just composed of grade 1 and grade 2
tumors, being all but one Ta. CCND1 amplification was
exclusively observed in CIN-positive samples, suggesting
that CCND1 might be involved in the generation of cen-
trosomal abnormalities [25]. Moreover, we showed
amplification of CCND1 as DMs in three CIN-positive
samples. To our knowledge, this is the first report in the
literature to show genomic amplification of CCND1 as
DMs in bladder tumors.
The differences between FISH and metaphase CGH
results for the CIN-positive samples highlight intratu-
moral heterogeneity. CGH detected the dominant geno-
mic alterations present in at least some 60% of the
tumor population [26]; however, it did not detect either
the alterations that appear in a small number of cells or
ongoing chromosomal instability. The association of
DMs, centrosome aberrations and intercellular CIN
observed in this study may indicate that the CIN pheno-
type does not become the major clonal population in
bladder cancer.
As expected, centrosome amplification is correlated
with CIN. Approximately, 75% (9/12) of CIN-positive
samples and none of the CIN-negative samples showed
centrosomal abnormalities. During the analysis of meta-
phase figures, multipolar and pseudo-bipolar spindles
were identified in some CIN-positive tumors with super-
numerary centrosomes. The presence of extra centro-
somes within tumor cells might be deleterious as
multipolar mitosis may generate sufficient high levels of
aneuploidy to compromise cell viability. Several cancer
cell lines overcome this problem by clustering their
extra centrosomes at the two poles of the spindle, thus
ensuring bipolar chromosome segregation [27-29]. This
phenomenon was observed in some samples in the pre-
sent study showing abnormal large centrosomes and
bipolar spindles, what confirms that centrosome cluster-
ing occurs in bladder cancer. It is interesting to note
that bipolar spindles were also observed in three CIN-
positive samples displaying a string-like centrosome
similar to what was observed by Pihan et al. [30] in
malignant tumors and tumor-derived cell lines.
In addition, the high chromosomal instability observed
in our samples with centrosome clustering suggests that
other factors might cause chromosomal instability. In
fact, chromosome lagging, defined as a delayed move-
ment of one chromatide in anaphase, was observed
when anaphasic cells were studied. This is consistent
with studies carried out by Thompson and Compton
[31] on human cell lines, where the authors identified
defective kinetochore-spindle attachments leading to
anaphase lagging as a cause of chromosome missegrega-
tion. Recently, Ganem et al. [32] demonstrated that
Table 2 DM localization on metaphase plate and micronuclei frequencies
Peripheral localization of
DMs
CCND1 Positive
MN
CEP11 positive
MN
Total MN
Sample
per
metaphase
per 100
metaphase
per
nuclei
per 100
nuclei
per
nuclei
per 100
nuclei
per
nuclei
per 100
nuclei
U-150 22/25 88.00% 28/472 5.93% 1/472 0.21% 62/472 13.14%
U-076 27/36 75.00% 19/477 3.98% 1/477 0.21% 48/477 10.06%
U-866 15/20 75.00% 10/412 2.43% 10/412 2.43% 42/412 10.19%
DM: Double minute, MN: Miclonuclei, CEP: Centromere
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extra centrosomes alone are sufficient to promote chro-
mosome missegregation during bipolar cell division.
According to these authors, cells passing a transient
multipolar spindle intermediate accumulate merotelic
kinetochore-spindle attachment errors before centro-
some clustering and anaphase.
DNA sequence amplification is one of the hallmarks
of genomic instability in cancer. The target genes driv-
ing the 11q13 amplicon have been extensively reported,
and at least four cores of amplification have been estab-
lished in breast cancer [33,34]. However, the evolution
of this amplicon in tumor cells remains unclear. The
11q13 amplicon is usually located in the same chromo-
somal region as the amplified target gene [7,8,35,36]. In
our study, HSRs were usually located in the same chro-
mosomal region as the amplified target genes, thus
strongly supporting the hypothesis that the 11q13
amplicon is of intrachromosomal origin [8]. The pre-
sence of dicentric chromosomes and anaphase bridges
in cell populations undergoing amplification is consis-
tent with the role of the breakage-fusion-bridge (BFB)
cycle in explaining intrachromosomal amplifications
[37]. In the present study, the HSR-bearing chromosome
11 was often observed to be involved in nucleoplasmatic
bridges and dicentric chromosomes.
Nevertheless, several mechanisms for the genesis of
extrachromosomal amplifications (i.e., DMs) have been
proposed [38]. A yeast model system was used to
demonstrate that hairpin-capped double-strand breaks
occurring at the location of human Alu-quasipalin-
dromes trigger both DM and HSR gene amplification.
According to this model, the nature of the amplicons
depends on the chromosomal location of the amplified
gene relative to double-strand break formation [39].
Within our sample set, the co-existence of CCND1
amplification in DMs and HSR is noteworthy. In tumor
samples with both types of amplification, metaphasic
cells with both HSR and DMs were observed in the
transition zone between the HSR and DM carrier cell
sub-populations. These data demonstrate a striking cor-
relation between the presence of DMs and the observed
fragmentation of HSR, thus suggesting a possible
mechanism for excising amplified sequences in HSRs,
giving rise to DMs. A similar phenomenon has been
described in human cell lines with dihydrofolate-resis-
tance gene amplification [40,41]. Our findings strongly
suggest that the same mechanism operates in tumor
cells in vivo. Moreover, as seen in patient U-443, frag-
mentation of the HSR might occur in a metastatic form,
after remaining stable for a long period of time in the
primary tumor.
All samples with DMs also exhibited micronuclei;
approximately 50% of them were CCND1-positive. The
fact that the CCND1 signal was not present in the
remaining 50% of the micronuclei indicates that other
genomic regions were being actively eliminated from
these cells. These findings suggest that micronuclei
extrusion could induce rapid and dramatic changes, not
only in the CCND1 gene with DMs, but also in other
acentric fragments or even affecting whole chromosome
copy numbers, therefore exacerbating genomic instabil-
ity. The removal of amplified CCND1 sequences by
micronuclei extrusion in bladder tumor cells was consis-
tent with results reported by Valent et al. [42] regarding
DMs containing MYCN neuroblastoma. Furthermore, in
the present study, some cells showed one to three copies
of the CCND1 on chromosome 11, but with an adjacent
CCND1-positive micronucleus, suggesting that in some
cells the normal copy number for this gene is restored
by DMs extrusion.
It is known that centrosome amplification is a source
of CIN, as are chromosomal lagging and micronuclei
formation. Centrosome clustering partially reduces chro-
mosomal instability [28], and increases cell viability by
avoiding multipolar mitosis. Our observations that cen-
trosome clustering is a common feature of chromoso-
mally unstable bladder tumors, and the appearance of
new drugs that specifically target centrosome clustering,
such as griseofulvin [43], highlights the importance of
further studying the role of centrosome abnormalities in
bladder cancer.
Conclusions
The present study describes the in vivo behavior of
CCND1 amplification in chromosome unstable T1 blad-
der tumors. We also demonstrate that the coalescence
of centrosomes into two functional spindle poles is a
common feature of these tumors.
Our study is the first report in the literature regarding
the simultaneous CCND1 amplification in DM and HSR
in bladder cancer cells. Our findings suggest a striking
correlation between HSR fragmentation and the appear-
ance of DMs which subsequently are removed by micro-
nuclei extrusion. Of interest, we found that only those
patients whose tumors showed CCND1 amplification in
DMs had a significantly shorter overall survival rate.
Further studies in a larger sample size should be neces-
sary in order to confirm our results.
Coalescence of supernumerary centrosomes was
observed in 80% of the most unstable tumors, highlight-
ing the importance of this phenomenon in bladder
cancer.
Data presented here contribute to the understanding
of the in vivo chromosome behavior of bladder tumor
cells, and show how its complexity could be analyzed by
FISH on paraffin embedded tumors as if snapshots of
what occurs in the tumor at the time of surgical
removal had been taken.
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